118.64
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Axsome Therapeutics Schedule Third Quarter 2025 Financial Results Announcement and Conference Call - Quiver Quantitative
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 - The Manila Times
Q3 2025 Results Nov 3: Axsome Therapeutics to Report Results and Host 8:00 AM ET Conference Call; Webcast - Stock Titan
Is Axsome Therapeutics Inc 19X a good long term investmentVolatility Adjusted Trading & Free Trading Psychology Sessions - earlytimes.in
Can Axsome Therapeutics Inc. stock withstand economic slowdownWeekly Trade Analysis & Verified Momentum Stock Alerts - newser.com
Will Axsome Therapeutics Inc. (19X) stock outperform global peersM&A Rumor & High Conviction Trade Alerts - newser.com
J. Safra Sarasin Holding AG Purchases 9,998 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Meet Herriot Tabuteau, The Haitian-Born Doctor Whose Brain Disorder Medications Turned Into A $6 Billion Empire - Black Enterprise
What is B. Riley's Estimate for AXSM Q3 Earnings? - MarketBeat
Real time social sentiment graph for Axsome Therapeutics Inc.Take Profit & Weekly Breakout Stock Alerts - newser.com
Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation - Yahoo Finance
Migraine Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories - Barchart.com
Axsome Therapeutics (NASDAQ:AXSM) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat
B. Riley Securities Initiates Coverage of Axsome Therapeutics (AXSM) with Buy Recommendation - Nasdaq
AXSM: New 'Buy' Rating from B. Riley Securities with $179 PT | A - GuruFocus
How Axsome Therapeutics Inc. (19X) stock trades after rate cuts2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com
B. Riley Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $179 - 富途牛牛
Will Axsome Therapeutics Inc. (19X) stock deliver stable dividendsJuly 2025 Chart Watch & Risk Controlled Daily Trade Plans - newser.com
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN
H.C. Wainwright maintains Axsome stock Buy rating, $190 target - MSN
14 Best Biotech Stocks to Buy Right Now - Insider Monkey
Can Auvelity Drive Axsome's Growth Through the Rest of 2025? - The Globe and Mail
Obstructive Sleep Apnea Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma - Barchart.com
Obstructive Sleep Apnea Market Insights Highlight Expanding - openPR.com
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years - Mitrade
Axsome Sues Apotex to Block Copies of Symbravo Migraine Drug - Bloomberg Law News
Axsome Therapeutics ($AXSM) Is Paying a $7.75M Settlement to Investors — Here’s How to Get Your Shar - TradingView
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $148 - 富途牛牛
Axsome Settles Investors' Drug Approval Suit For $7.8M - Law360
Axsome Therapeutics ($AXSM) $7.75M Investor Settlement - TradingView
Axsome Therapeutics and $AXSM Investors Finalise $7.75M Settlement Agreement - TradingView
Cantor Fitzgerald Has Weak Forecast for AXSM FY2026 Earnings - MarketBeat
Assenagon Asset Management S.A. Cuts Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome therapeutics COO Jacobson sells $1.15 million in shares By Investing.com - Investing.com Canada
Axsome therapeutics COO Jacobson sells $1.15 million in shares - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) COO Mark L. Jacobson Sells 10,000 Shares - MarketBeat
Axsome to Settle Class Suit Over Migraine Drug for $7.75 Million - Bloomberg Law News
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Analysts - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) COO Sells $5,241,237.84 in Stock - MarketBeat
Pallas Capital Advisors LLC Purchases 2,492 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
10,400 Shares in Axsome Therapeutics, Inc. $AXSM Acquired by Strs Ohio - MarketBeat
Herriot Tabuteau Sells 15,254 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Herriot Tabuteau Sells 27,907 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Herriot Tabuteau Sells 19,719 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Market Moves: Can Axsome Therapeutics Inc. continue delivering strong returnsTrade Risk Assessment & Stepwise Swing Trade Plans - khodrobank.com
Intech Investment Management LLC Boosts Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
How Investors May Respond To Axsome Therapeutics (AXSM) Showcasing Late-Stage CNS Pipeline Data at Psych Congress - Yahoo Finance
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):